Four questions, one clearer conversation: how real-world data became a migraine tool clinicians actually use
Ask someone who lives with migraine how severe their attacks are, and the answer is rarely straightforward. For the specialist sitting opposite them, building a clear clinical picture from that account, and deciding what comes next, is a lot harder than it should be.
Standard migraine questionnaires such as MIDAS and HIT-6 have served research well for years, but they were never designed to open up a dialogue between patient and doctor. Both lean heavily on disability, and they ask people to recall weeks or months of symptoms, which brings its own blind spots. Patients and key opinion leaders (KOLs) had identified a genuine need: a short, robust severity measure that would hold up as well in a busy clinic as in a real-world study, and signal when treatment should be reconsidered or a referral may be needed.
Listening first
Before a single question was drafted, Prescient brought the people who would rely on the new measure into the process to help define it. Through advisory boards with patients and clinicians, we agreed what it had to achieve and where existing patient-reported outcomes were falling short. From there, a steering committee of 11 KOLs from seven European countries guided the work, keeping it grounded in everyday practice.
Letting the data lead
Rather than starting from theory, we started from evidence. Our team analyzed clinic diary registries, which capture patients’ migraine experiences day to day. Drawing on more than 1,000 patient records, we identified which questions should form part of the new measure, set how responses would be scored, and compared the resulting system with established disability scales. What emerged was strikingly lean: four items, brief enough to complete in moments, yet built around what matters to patients.
Earning clinicians’ trust
A simple tool is only useful if doctors have confidence in it, so we put it through rigorous psychometric validation in 555 Spanish- and English-speaking patients, following COSMIN standards, a widely used international framework for assessing health measurement instruments. The analyses examined its underlying structure, whether results stayed consistent when patients completed it a second time, and whether it measured the same thing in both languages. The findings confirmed the score as valid and reliable.
From manuscript to the wider community
Strong science still has to reach its audience. Prescient conducted all analyses and co-authored the manuscript, the congress abstracts, and the responses to peer reviewers. Early findings were presented at the European Headache Congress in Lisbon (2024), the International Headache Congress in São Paulo (2025), and the European Academy of Neurology (EAN) Congress in Helsinki (2025), building momentum well ahead of full publication.
We also coordinated KOL input as the tool was adapted for new languages, and supported medical education for non-specialist healthcare professionals, helping them gauge whether someone’s migraine calls for specialist attention.
Recognition, then adoption
The paper describing the European Migraine & Headache Alliance (EMHA) migraine scoring system was published open access in Cephalalgia in 2026, with Prescient among its authors. The journal’s editor, Professor Simona Sacco, then selected it as Editor’s Essential Reading for September 2026, a distinction reserved for articles the headache community shouldn’t miss. The International Headache Society also featured it on LinkedIn.
Even more telling is what happened next. The score is available to physicians and patients through the EMHA website. A global pharmaceutical company has incorporated it into a UK real-world study, and a leading UK academic headache group is using it in investigator-initiated research. Two language versions have been published, a further 12 have been validated and are awaiting publication, and another 10 are in progress.
The bigger picture
What set this project apart was continuity. The same team involved in framing the questions also mined the data, ran the psychometrics, co-authored the paper, and worked alongside KOLs to carry the score into practice. Nothing was lost in the handover between stages, because there was no handover.
That is the real promise of end-to-end RWE support. Instead of ending its life in a journal, evidence can be translated into a tool that gives patients and clinicians a common language for discussing migraine severity and deciding on the appropriate course of care.
Click the link to read the publication: https://journals.sagepub.com/doi/10.1177/03331024261471185